基因组编辑市场规模、份额、成长分析、按技术、交付方式、应用、模式、最终用途、地区 - 产业预测 2025-2032

基因组编辑市场规模预计将在 2023 年达到 59.2 亿美元，并从 2024 年的 68.7 亿美元增长到 2032 年的 226.9 亿美元，预测期内（2025-2032 年）的复合年增长率为 16.1%。

随着企业追求竞争优势，基因组编辑市场正经历适度的併购活动。尤其是 Ginkgo Bioworks 于 2024 年 1 月收购 Proof Diagnostics 凸显了这一趋势，扩大了该公司的医学遗传学产品组合。该领域的成长得益于政府对合成生物学的有利监管、对基因和合成细胞的需求不断增加以及政府和大公司的大量投资。基因编辑和利用的创新策略正在涌现，促进了基因治疗和分子生物学的进步。在主要企业加大生产和市场渗透率的同时，卡罗莱纳生物供应公司和 ChristianaCare 基因编辑研究所合作创建 CRISPR 教育套件等专门倡议旨在提高该领域的认识和教育，预计这将进一步扩大市场。

目录

介绍

• 调查目的
• 定义
• 市场覆盖

调查方法

• 资讯采购
• 次要和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概览展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场动态
  • 驱动程式
  • 机会
  • 限制因素
  • 任务
• 波特的分析

关键市场考察

• 技术分析
• 价值链分析
• 市场生态系统
• 案例研究
• 专利分析
• 监管格局
• 创新矩阵
• 重大投资分析
• 关键成功因素
• 竞争程度

基因组编辑市场（依技术划分）

• 市场概览
• (CRISPR)/Cas9
• TALENs/MegaTALs
• ZFN
• Meganuclease
• 其他的

按交付方式分類的基因组编辑市场

• 市场概览
• 体外
• 体内

基因组编辑市场（按应用）

• 市场概览
• 基因工程
  • 细胞株工程
  • 动物基因工程
  • 植物基因工程
  • 其他的
• 临床应用
  • 诊断
  • 开发治疗方法

基因组编辑市场（按模式）

• 市场概览
• 合约
• 内部

基因组编辑市场（依最终用途划分）

• 市场概览
• 生物技术和製药公司
• 学术和政府研究组织
• 合约研究组织

各地区基因组编辑市场规模

• 市场概览
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲（MEA）
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争格局

• 前五大公司对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Merck KGaA（Germany）
• Cibus Inc（US）
• Recombinetics（US）
• Sangamo Therapeutics（US）
• Editas Medicine（US）
• Precision BioSciences（US）
• CRISPR Therapeutics（Switzerland）
• Intellia Therapeutics, Inc（US）
• Caribou Biosciences, Inc.（US）
• Cellectis SA（France）
• AstraZeneca（UK）
• Takara Bio Inc.（Japan）
• Horizon Discovery Ltd.（Revvity, Inc.）（UK）
• Danaher Corporation（US）
• Transposagen Biopharmaceuticals, Inc.（US）
• Genscript Biotech Corp（China）
• New England Biolabs（US）
• OriGene Technologies, Inc.（US）
• bluebird bio, Inc（US）
• Lonza（Switzerland）
• Thermo Fisher Scientific, Inc.（US）

结论和建议

Genome Editing Market size was valued at USD 5.92 billion in 2023 and is poised to grow from USD 6.87 billion in 2024 to USD 22.69 billion by 2032, growing at a CAGR of 16.1% during the forecast period (2025-2032).

The Genome Editing Market is experiencing moderate merger and acquisition activity as industry players seek competitive advantages. Notably, Ginkgo Bioworks' acquisition of Proof Diagnostics in January 2024 highlights this trend, broadening its medical genetics portfolio. The sector's growth is fueled by favorable government regulations on synthetic organisms, a rising demand for genes and synthetic cells, and substantial investments from governments and major corporations. Innovative strategies for gene editing and exploitation are emerging, driving advancements in gene therapy and molecular biology. Key players are enhancing productivity and market reach while specialized initiatives, such as the collaboration between Carolina Biological Supply Company and Christianacare Gene Editing Institute to create CRISPR educational kits, aim to increase awareness and education in the field, promising further market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Genome Editing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Genome Editing Market Segments Analysis

Global Genome Editing Market is segmented by Technology, Delivery Method, Application, Mode, End-use and region. Based on Technology, the market is segmented into (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease and Others. Based on Delivery Method, the market is segmented into Ex-vivo and In-vivo. Based on Application, the market is segmented into Genetic Engineering, Clinical Applications. Based on Mode, the market is segmented into Contract and In-house. Based on End-use, the market is segmented into Biotechnology and pharmaceutical companies, Academic and government research institutes andContract research organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Genome Editing Market

The Genome Editing market is experiencing significant growth, particularly in the agricultural sector, where it's increasingly utilized to enhance crop traits such as drought resistance, pest resilience, and nutritional value. As advancements in genome editing technology continue, agriculture is poised to benefit even more from these innovations. The CRISPR technology, in particular, has revolutionized the ability to develop crops at an accelerated pace, driving demand within this market. As farmers and consumers alike seek more sustainable and nutrient-rich food options, the application of genome editing techniques will play a crucial role in shaping the future of agriculture.

Restraints in the Genome Editing Market

The Genome Editing market faces notable constraints due to ethical concerns surrounding the technology, particularly regarding its application in human embryos and bacterial cells. These ethical dilemmas have led to stringent regulatory frameworks that complicate the approval process for genome enhancement therapies, ultimately hindering market expansion. Consequently, many countries have implemented strict guidelines that act as a barrier, stalling research and development efforts in the field. As a result, the apprehension over potential misuse and the moral implications of genome editing continues to impact innovation and progress, thereby restraining the overall growth of the market.

Market Trends of the Genome Editing Market

The Genome Editing market is witnessing a significant trend driven by its expanding application in agriculture, particularly in response to global food security challenges. Technologies like CRISPR are revolutionizing crop production by enabling the creation of genetically modified crops that exhibit enhanced traits such as drought tolerance, pest resistance, and improved nutritional profiles. This rapid and precise approach to crop improvement is positioning genome editing as a key solution to meet the increasing demand for sustainable agriculture. As concerns over climate change and food scarcity intensify, genome editing technologies are expected to play a pivotal role in shaping the future of agricultural practices, significantly driving market growth.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case Studies
• Patent Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Genome Editing Market by Technology

• Market Overview
• (CRISPR)/Cas9
• TALENs/MegaTALs
• ZFN
• Meganuclease
• Others

Genome Editing Market by Delivery Method

• Market Overview
• Ex-vivo
• In-Vivo

Genome Editing Market by Application

• Market Overview
• Genetic Engineering
  • Cell Line Engineering
  • Animal Genetic Engineering
  • Plant Genetic Engineering
  • Others
• Clinical Applications
  • Diagnostics
  • Therapy Development

Genome Editing Market by Mode

• Market Overview
• Contract
• In-house

Genome Editing Market by End-use

• Market Overview
• Biotechnology and pharmaceutical companies
• Academic and government research institutes
• Contract research organizations

Genome Editing Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cibus Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recombinetics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision BioSciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics, Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caribou Biosciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellectis S.A (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Discovery Ltd. (Revvity, Inc.) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transposagen Biopharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genscript Biotech Corp (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• New England Biolabs (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OriGene Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bluebird bio, Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations